Cyclooxygenase-2 promotes tumor lymphangiogenesis and lymph node metastasis in oral squamous cell carcinoma

International Journal of Oncology

Volumn 41, Issue 3, 2012, Pages 885-892

  Morita, Yoshihiro ^a   Hata, Kenji ^a   Nakanishi, Masako ^a   Nishisho, Toshihiko ^a   Yura, Yoshiaki ^a   Yoneda, Toshiyuki ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Cyclooxygenase 2; Lymph node metastasis; Lymphangiogenesis; Oral squamous cell carcinoma

Indexed keywords

CYCLOOXYGENASE 2; VASCULOTROPIN C;

ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CARCINOGENESIS; CONTROLLED STUDY; ENZYME INACTIVATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; MALE; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; MOUSE; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MOUTH NEOPLASMS; NITROBENZENES; SULFONAMIDES; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 84864969156     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1529     Document Type: Article

References (47)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Hunter KD, Parkinson EK and Harrison PR: Profiling early head and neck cancer. Nat Rev Cancer 5: 127-135, 2005. (Pubitemid 40220338)
3. Forastiere A, Koch W, Trotti A and Sidransky D: Head and neck cancer. N Engl J Med 345: 1890-1900, 2001. (Pubitemid 33716564)
4. Gil Z, Carlson DL, Boyle JO, et al: Lymph node density is a significant predictor of outcome in patients with oral cancer. Cancer 115: 5700-5710, 2009.
5. Mamelle G, Pampurik J, Luboinski B, Lancar R, Lusinchi A and Bosq J: Lymph node prognostic factors in head and neck squamous cell carcinomas. Am J Surg 168: 494-498, 1994. (Pubitemid 24345707)
6. Joukov V, Pajusola K, Kaipainen A, et al: A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15: 1751, 1996. (Pubitemid 26112397)
7. Mandriota SJ, Jussila L, Jeltsch M, et al: Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 20: 672-682, 2001. (Pubitemid 32167632)
8. Stacker SA, Caesar C, Baldwin ME, et al: VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 7: 186-191, 2001. (Pubitemid 32148485)
9. Skobe M, Hawighorst T, Jackson DG, et al: Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 7: 192-198, 2001. (Pubitemid 32148486)
10. Sleeman JP and Thiele W: Tumor metastasis and the lymphatic vasculature. Int J Cancer 125: 2747-2756, 2009.
11. Makinen T, Veikkola T, Mustjoki S, et al: Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J 20: 4762-4773, 2001. (Pubitemid 32848629)
12. Roberts N, Kloos B, Cassella M, et al: Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res 66: 2650-2657, 2006.
13. Shimizu K, Kubo H, Yamaguchi K, et al: Suppression of VEGFR-3 signaling inhibits lymph node metastasis in gastric cancer. Cancer Sci 95: 328-333, 2004. (Pubitemid 38519473)
14. Veikkola T, Jussila L, Makinen T, et al: Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J 20: 1223-1231, 2001. (Pubitemid 32233963)
15. Burton JB, Priceman SJ, Sung JL, et al: Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Res 68: 7828-7837, 2008.
16. Alitalo K and Carmeliet P: Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 1: 219-227, 2002. (Pubitemid 41039145)
17. Dadras SS, Paul T, Bertoncini J, et al: Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol 162: 1951-1960, 2003. (Pubitemid 36613052)
18. Karpanen T and Alitalo K: Lymphatic vessels as targets of tumor therapy? J Exp Med 194: F37-F42, 2001. (Pubitemid 32983007)
19. Wu KK: Inducible cyclooxygenase and nitric oxide synthase. Adv Pharmacol 33: 179-207, 1995.
20. Tsujii M, Kawano S and DuBois RN: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94: 3336-3340, 1997. (Pubitemid 27157312)
21. Vane JR, Mitchell JA, Appleton I, et al: Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc Natl Acad Sci USA 91: 2046-2050, 1994. (Pubitemid 24092039)
22. Prescott SM and Fitzpatrick FA: Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta 1470: M69-M78, 2000. (Pubitemid 30155608)
23. Oshima M, Dinchuk JE, Kargman SL, et al: Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87: 803-809, 1996. (Pubitemid 26404280)
24. Fujita T, Matsui M, Takaku K, et al: Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res 58: 4823-4826, 1998. (Pubitemid 28503676)
25. Rozic JG, Chakraborty C and Lala PK: Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer 93: 497-506, 2001. (Pubitemid 32701408)
26. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M and DuBois RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93: 705-716, 1998. (Pubitemid 28257578)
27. Williams CS, Tsujii M, Reese J, Dey SK and DuBois RN: Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 105: 1589-1594, 2000. (Pubitemid 30390309)
28. Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT and Masferrer JL: Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 62: 625-631, 2002. (Pubitemid 34126930)
29. Masferrer JL, Leahy KM, Koki AT, et al: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60: 1306-1311, 2000. (Pubitemid 30151999)
30. Takahashi K, Kanazawa, Akiyama et al: Establishment and characterization of a cell line (SAS) from poorly differentiated human squamous cell carcinoma of the tongue. J Jpn Stomatol Soc 38: 20-28, 1989.
31. Shintani S, Mihara M, Nakahara Y, et al: Lymph node metastasis of oral cancer visualized in live tissue by green fluorescent protein expression. Oral Oncol 38: 664-669, 2002. (Pubitemid 34880104)
32. Iwata C, Kano MR, Komuro A, et al: Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis. Cancer Res 67: 10181-10189, 2007. (Pubitemid 350070790)
33. Hida T, Yatabe Y, Achiwa H, et al: Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 58: 3761-3764, 1998. (Pubitemid 28405625)
34. Ristimaki A, Honkanen N, Jankala H, Sipponen P and Harkonen M: Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 57: 1276-1280, 1997. (Pubitemid 27152551)
35. Sano H, Kawahito Y, Wilder RL, et al: Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 55: 3785-3789, 1995.
36. Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE and Schror K: Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 59: 198-204, 1999. (Pubitemid 29062978)
37. Choe MS, Zhang X, Shin HJ, Shin DM and Chen ZG: Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol Cancer Ther 4: 1448-1455, 2005.
38. Mendes RA, Carvalho JF and Waal I: An overview on the expression of cyclooxygenase-2 in tumors of the head and neck. Oral Oncol 45: e124-e128, 2009.
39. Da MX, Wu XT, Wang J, et al: Expression of cyclooxygenase-2 and vascular endothelial growth factor-C correlates with lymphangiogenesis and lymphatic invasion in human gastric cancer. Arch Med Res 39: 92-99, 2008. (Pubitemid 350192014)
40. Su JL, Shih JY, Yen ML, et al: Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma. Cancer Res 64: 554-564, 2004.
41. Zhang XH, Huang DP, Guo GL, et al: Coexpression of VEGF-C and COX-2 and its association with lymphangiogenesis in human breast cancer. BMC Cancer 8: 4, 2008.
42. Di JM, Zhou J, Zhou XL, et al: Cyclooxygenase-2 expression is associated with vascular endothelial growth factor-C and lymph node metastases in human prostate cancer. Arch Med Res 40: 268-275, 2009.
43. Oka M, Iwata C, Suzuki HI, et al: Inhibition of endogenous TGF-beta signaling enhances lymphangiogenesis. Blood 111: 4571-4579, 2008.
44. Zwaans BM and Bielenberg DR: Potential therapeutic strategies for lymphatic metastasis. Microvasc Res 74: 145-158, 2007. (Pubitemid 350051029)
45. Burton JB, Johnson M, Sato M, et al: Adenovirus-mediated gene expression imaging to directly detect sentinel lymph node metastasis of prostate cancer. Nat Med 14: 882-888, 2008.
46. Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420-1428, 2009.
47. Wendt MK, Allington TM and Schiemann WP: Mechanisms of the epithelial-mesenchymal transition by TGF-beta. Future Oncol 5: 1145-1168, 2009.